Betaine (TMG)

The VerdictMODERATE CONVICTION

Betaine gives trained adults a small lower-body strength gain at 2.5g a day, and almost nothing else the marketing claims.

Before you buy betaine, ask one question — are you a trained adult running structured progressive overload looking for a small lower-body strength edge? If yes, plain TMG anhydrous powder at 2.5g/day is a cheap trial. If no — especially if you're buying it for fat loss or testosterone — save your money.

In trained adults at 2.5g a day for 6+ weeks, betaine gives a small-to-moderate boost on lower-body lifts like the squat. The 2022 meta-analysis says it does NOT improve body composition — that claim was based on one small study that didn't survive pooling.
Most people get wrong: betaine is NOT a "natural creatine alternative." The clearest head-to-head trial measured muscle directly and found creatine raised muscle phosphocreatine and strength; betaine raised neither.

Betaine (also called TMG) is a small molecule found naturally in beets, spinach, and wheat. It works like the lubricant in an engine — it lets one specific chemical reaction in your body run more smoothly, and it parks itself inside muscle cells as a kind of cellular shock absorber. The engine still needs fuel, structure, and miles for power to build; betaine just removes a small bit of friction.

That's the general answer. Your stack is different.

Check your whole stack

Before you buy betaine, ask one question: are you a resistance-trained adult running structured progressive overload, looking for a small lower-body strength edge?

If yes, plain TMG anhydrous powder at 2.5g a day for 6+ weeks is a cheap trial. If you're buying it for fat loss, testosterone, or "natural energy," save the money — the meta-analyses do not support those claims.

The Protocol

Population	Dose	Timing	Form	Loading
Resistance-trained adult (strength goal)	2.5 g/day	Once daily with food	TMG anhydrous powder/capsules	No loading
In-season team-sport athlete	2 g/day	Daily with breakfast, full season	TMG anhydrous	No loading
Elevated homocysteine (post-B-vitamin optimisation)	3-6 g/day	Split AM/PM with meals	TMG anhydrous	No loading
Healthy "wellness" adult	Not routinely indicated — no evidence base for general use
Adult on lipid-management protocol	Not indicated without baseline + 8-12 wk follow-up lipid panel (Ashtary-Larky 2021 SR/MA shows modest pooled total cholesterol rise at chronic 3-6g/d)
Homocystinuria (rare inborn error)	6 g BID	Twice daily	Cystadane (Rx)	No loading

Forms — the rare supplement with no premium-form trap

TMG Anhydrous Powder

Effectively complete oral absorption

Everything — strength, homocysteine, in-season athletes. The cost-rational form.

£4-7/month at 2.5g/day

TMG Anhydrous Capsules

Same active ingredient

Convenience only — no PK advantage

£8-12/month

Betaine HCl

Same molecule + HCl moiety

Marketed for digestion (hypochlorhydria) — NOT for performance specifically

£10-20/month

"Liposomal" / Enhanced

No human PK data

Not justified by current evidence — premium pricing without trial support

£15-30/month

Absorption tips: Take with food for GI comfort. Split into 1.25g x 2 if GI tolerance is an issue at once-daily 2.5g. No documented cofactor requirements or absorption inhibitors at supplemental doses. The buried point: TMG anhydrous powder = prescription Cystadane = same active ingredient at the same site of action.

Safety & Interactions

Modest total cholesterol elevation at chronic 3-6g/day

Pooled SR/MA evidence (Ashtary-Larky 2021 PMID 31809615) shows total cholesterol creeps up at chronic supplemental doses, likely via hepatic PEMT activation increasing VLDL secretion. If you're on lipid management or have elevated LDL-C: baseline + 8-12 wk follow-up lipid panel before going long-term.

Methotrexate / folate-affecting anticonvulsants

Theoretical interaction via competing methylation pathways. No clinical interaction signals documented at supplemental doses in healthy adults. Discuss with prescriber before chronic supplementation.

GI tolerance ceiling

Diarrhoea and nausea uncommon at 2.5 g/day, common at ≥6 g/day. "Fishy" body odour (trimethylaminuria-like) at higher doses; some individuals genetically more susceptible (FMO3 variants). Split-dose if needed.

Contraindicated populations

Adults with active dyslipidaemia management: chronic-dose lipid signal adds risk without clear benefit for non-strength goals.
Pregnant or lactating women: insufficient human supplementation safety data; dietary background intake is fine.
Children and adolescents (non-homocystinuric): insufficient safety data; no efficacy justification for performance use.

Upper limit

Tolerable Upper Intake Level (UL): none set by EFSA, NIH, or US IOM. Observed safe level: ~9-15 g/day short-term in industry-funded review literature. Homocystinuria treatment runs to 20 g/day under medical supervision.

Conviction

MODERATE — endpoint-stratified

Homocysteine reduction 3-6 g/d HIGH
Lower-body strength resistance-trained 2.5 g/d ≥6 wk MODERATE
In-season team-sport performance 2 g/d MODERATE
DNA methylation biomarker shifts MODERATE (biomarker-only)
Body composition (fat / lean mass standalone) DEBUNKED-by-pooling
Endurance / aerobic performance LOW
Muscle PCr "creatine-mimetic" claim DEBUNKED
Acute anabolic endocrine signalling MODERATE (biomarker-only)
Serum testosterone elevation LOW (single unreplicated RCT)
Cognitive / dementia prevention LOW
Total cholesterol elevation (NEGATIVE=HARM safety signal) MODERATE
Cardiovascular hard outcomes NONE
Homocystinuria clinical indication (prescription Cystadane) HIGH
Premium-form clinical-outcome superiority NONE

What would change this

For strength: An independent, non-industry-funded, double-blind, placebo-controlled, ≥12-week RCT of N≥80 resistance-trained adults on standardised periodised training, 2.5 g/day betaine, with primary endpoint of bench press 1RM AND back squat 1RM, showing >5% absolute strength advantage with CI excluding zero, would upgrade to HIGH.

For body composition: A pre-registered ≥16-week RCT of N≥120 with DXA primary endpoint powered to detect 0.5 kg between-group difference would re-open the body-composition question.

For testosterone: An independent (non-Aziz-lab) double-blind RCT of N≥60 trained adults at 2.5 g/day × 8+ weeks with LC-MS-measured serum testosterone as pre-specified primary, showing >10% elevation vs placebo, would upgrade testosterone from LOW to MODERATE.

For lipid safety: Long-term (≥6 month) lipid + TMAO data at 3-6 g/day would either confirm or relax the total-cholesterol elevation flag.

Worth Your Money?

Weekly cost£1-3/week at 2.5 g/day of plain TMG anhydrous powder. Premium "liposomal" forms £3-7/week with no PK justification.

Worth it ifYou're a resistance-trained adult running structured progressive overload looking for a small lower-body strength edge, or an in-season team-sport athlete. The strength benefit is modest but real.

Lower priority ifYour training is inconsistent, your protein is low, or your sleep is poor — your next £10 is likely better spent on training consistency, protein, or sleep than on adding betaine. Lower priority again if you're chasing fat loss, testosterone, or "natural energy" claims the evidence does not support.

Conditional Value

Go Deeper

Want to stop wasting money on supplements that don't work? The Verdict reviews one every week — free.

Subscribe to The Verdict

Claims vs Evidence — See What the Research Found

What People Claim

Marketing positions betaine as a "natural cell volumiser" that does what creatine does without the water weight, an ergogenic that boosts strength and muscle gain across the board, and increasingly a "natural testosterone booster" off a single 2023 CrossFit RCT. The longevity-supplement aisle adds an epigenetic angle ("methyl donor for healthy aging"), and the digestion aisle sells betaine HCl for stomach acid support.

The biology behind these claims is real at the mechanism level — betaine genuinely donates a methyl group to homocysteine and does accumulate inside skeletal muscle as an osmolyte. Those two mechanisms anchor every clinical pitch that follows. The disconnect is between what the mechanisms can plausibly do and what the human trial literature has actually demonstrated, which is a much narrower picture.

What the Evidence Actually Shows

Claim	Evidence	Effect	Key Study	Verdict
Homocysteine reduction (3-6 g/d)	STRONG	~12% drop at 6 g/d	Olthof 2003 PMID 14652361 (N=72 dose-finding)	Works
Lower-body strength (2.5 g/d ≥6 wk, trained)	MODERATE	Small-to-moderate 1RM gain	Miller 2024 SR/MA PMID 39514262 (17 trials N=317)	Works modestly
In-season team-sport performance	MODERATE	Selected match metrics improved	Pérez-Quintero 2021 PMID 34663363 (pro youth football)	Works in context
Body composition (fat / lean mass standalone)	DEBUNKED-by-pooling	NULL pooled	Yu 2022 SR/MA PMID 34743773	Doesn't work
"Creatine-mimetic" PCr loading	DEBUNKED	No PCr rise (MRS-measured)	del Favero 2012 PMID 21744011 (head-to-head)	Doesn't work
Endurance / aerobic performance	WEAK	Mixed; not strong-effect	Trepanowski 2011 PMID 22080324	Probably doesn't
Acute post-exercise GH / IGF-1 / Akt	MODERATE	Elevated vs placebo (biomarker)	Apicella 2013 PMID 22976217	Biomarker, not outcome
Serum testosterone elevation	WEAK	+~7% in one CrossFit RCT, unreplicated	Aziz 2023 PMID 37409757	Hypothesis-generating only
DNA methylation pattern modification	MODERATE	Documented pattern shifts	Methyl-donor SR/MA PMID 37935134	Biomarker, not outcome
Cognitive function / dementia prevention	WEAK	Cross-sectional association only	Bidulescu 2007 PMID 17537289 (Dutch elderly cohort)	Unproven
Cardiovascular hard outcomes	NONE	No RCT	—	Not evaluated
Total cholesterol (SAFETY signal, NEGATIVE=HARM)	MODERATE	Modest pooled INCREASE at 3-6 g/d	Ashtary-Larky 2021 SR/MA PMID 31809615	Watch — flag for dyslipidaemia
Homocystinuria (rare inborn error)	STRONG	Prescription indication	Cystadane FDA approval	Works (Rx only)
Premium / liposomal / enhanced form superiority	NONE	No head-to-head data	—	Not justified

What would change this: Independent ≥12-week N≥80 RCT on strength endpoints; pre-registered ≥16-week N≥120 RCT with DXA body-composition primary; non-Aziz-lab replication of testosterone finding with LC-MS measurement.

The Full Picture — Mechanism, Debate & Nuance

How It Works

Job 1 — methyl donor in the homocysteine cycle. Betaine donates one of its three methyl groups to homocysteine via the enzyme betaine-homocysteine methyltransferase (BHMT), regenerating methionine and producing dimethylglycine. This is the alternative pathway to the more famous folate/B12 methionine synthase route. Olthof 2003 mapped the dose-response: 6 g/day drops fasting homocysteine ~12% in 6 weeks, with smaller effects at 3 g/day.

Job 2 — intracellular osmolyte. Betaine concentrates inside cells (especially muscle, liver, kidney) and works as a small organic osmolyte that defends cell volume against osmotic stress without disturbing protein folding. This is the mechanism behind the "cell volumisation" pitch. The mechanism is real. The question is whether that accumulation translates to measurable performance benefit, and the human trial literature says "small, primarily for lower-body strength, with structured training."

The third proposed mechanism is the cleanest debunk. del Favero 2012 ran a randomised double-blind head-to-head: creatine 20 → 5 g/day vs betaine 2 g/day for 10 days, with muscle PCr measured directly by ³¹P magnetic resonance spectroscopy. Creatine raised PCr and strength. Betaine did neither. Whatever benefit betaine provides during resistance training, it is not "loading muscle PCr." Treating betaine and creatine as interchangeable is a marketing convenience.

The Debate

Single positive RCT vs the meta-analysis

Cholewa 2014 PMC3844502 (N≈23, 2.5 g/d × 6 wk)

Improved arm size, bench work capacity, modest body-composition signal.

Yu 2022 SR/MA PMID 34743773 (~10 RCTs pooled)

NULL on body composition.

Single small positive RCT did not survive pooling. The meta-analysis is the better evidence; the marketing copy still leans on Cholewa 2014.

Pooled strength signal vs short under-powered RCT

Miller 2024 SR/MA + Cholewa 2017 SR

Small-to-moderate strength benefit, clearest on lower-body 1RM.

Branch 2020 (N=14, 6 wk CrossFit)

NULL — no hypertrophy or strength improvement.

Branch 2020 is short and under-powered. The pooled signal favours direction-positive; individual short trials miss it.

The 2023 testosterone surprise

Aziz 2023 PMID 37409757 (CrossFit RCT)

Betaine raised serum testosterone vs placebo (secondary endpoint).

No independent replication

Zero prior or subsequent RCTs in sweep replicate the testosterone effect.

One small unreplicated RCT. The fenugreek pattern (single positive RCT becomes a "natural T-booster" category) is the cautionary frame. Treat as hypothesis-generating only.

The creatine-mimetic claim vs the head-to-head

Marketing pitch

"Betaine works through cell volumisation, like creatine without the water weight."

del Favero 2012 PMID 21744011 (MRS-measured PCr)

Creatine raised muscle PCr and strength. Betaine raised neither.

Direct MRS measurement contradicts the creatine-mimetic claim. Betaine and creatine are different mechanisms; conflating them is convenient, not accurate.

Cardiovascular markers improve vs total cholesterol rises (same author group)

Ashtary-Larky 2022 PMID 33764214 (cardiovascular markers SR/MA)

Homocysteine drops, mixed lipid signal.

Ashtary-Larky 2021 PMID 31809615 (total cholesterol SR/MA)

Total cholesterol rises modestly.

Same author group, internally consistent. Methyl-donor activation of hepatic PEMT plausibly increases VLDL secretion. Not a contradiction — a stratified safety signal.

Honest Limitations

Training-state heterogeneity

Lab: positive RCTs run resistance-trained or in-season-team-sport adults on structured progressive overload. Reality: the average consumer is on inconsistent training, may not be lifting heavy enough to stress lower-body 1RM, and mixes betaine into a stack. Direction: real-world effect is smaller than trial effect, often indistinguishable from zero.

Body-composition over-claim

Lab: the 2014 Cholewa RCT is the body-comp anchor in marketing. Reality: the 2022 SR/MA pooled NULL, but marketing copy lags science by ~8 years and consumers buy betaine "for fat loss" based on outdated single-trial framing. Direction: buyers expect more than the current evidence supports.

Single-RCT testosterone hype

Lab: Aziz 2023 reported testosterone elevation as a secondary endpoint in one small CrossFit RCT. Reality: it's already being repackaged as a "natural T-booster" claim with no replication. Direction: the marketed claim outruns the evidence; consumers buying betaine for testosterone are buying a hypothesis.

The Nuance

Single molecule, no formulation trap. The buried point worth amplifying: TMG anhydrous powder, "performance betaine," and prescription Cystadane are the same active ingredient at the same site of action. Premium "liposomal" or "enhanced bioavailability" forms have no human PK data justifying the price. Buy plain bulk TMG powder at £4-7/month.

B-vitamin status comes first for homocysteine. If homocysteine is the goal, optimise folate, B12, and B6 before adding betaine. Betaine is the adjunct, not the lead intervention.

Food background intake is far below supplemental dose. Wheat bran, spinach, quinoa, sugar beets, and shellfish provide roughly 100-400 mg/day in a typical Western diet. That's background, not a supplemental dose — you can't eat your way to the 2.5 g/day used in the strength RCTs.

What doesn't work

Betaine for fat loss / body recomposition — Yu 2022 SR/MA pooled NULL across ~10 RCTs.
Betaine as a "natural creatine alternative" — direct MRS measurement says no.
Betaine for general "energy" or pre-workout stimulant effect — no acute ergogenic stimulant signal; pre-workout "energy" is the caffeine.
Premium "liposomal" or "enhanced bioavailability" betaine — no human PK or clinical-outcome trial supports the premium.
Betaine for testosterone elevation as an established outcome — built on one unreplicated RCT.
Betaine HCl for performance — HCl form is sold for stomach acid support, not performance.
Betaine for cognitive enhancement / dementia prevention — only observational evidence.
Betaine for anti-aging / longevity — no human longevity or healthspan RCT. Biomarker shifts are not outcomes.

Sources

Olthof MR, et al. (2003). Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. PMID 14652361. Dose-finding RCT, N=72, 6 wk. ~12% tHcy drop at 6 g/day.
Schwab U, et al. (2006). Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. J Nutr. PMID 16365055.
Cholewa JM, et al. (2017). Effects of Betaine Supplementation on Muscle Strength and Power: A Systematic Review. PMID 28426517.
Yu Q, et al. (2022). Betaine supplementation fails to improve body composition: a systematic review and meta-analysis. J Int Soc Sports Nutr. PMID 34743773. NULL primary.
Miller A, et al. (2024). Effects of chronic betaine supplementation on exercise performance: Systematic review and meta-analysis. Nutrients. PMID 39514262. 17 trials, N=317. Most recent synthesis anchor.
Ashtary-Larky D, et al. (2022). Effects of betaine supplementation on cardiovascular markers: A systematic review and Meta-analysis. Crit Rev Food Sci Nutr. PMID 33764214.
Ashtary-Larky D, et al. (2021). Betaine Supplementation Moderately Increases Total Cholesterol Levels: A Systematic Review and Meta-Analysis. Pharmacol Res. PMID 31809615. Safety signal.
Pérez-Quintero M, et al. (2021). Effects of chronic betaine supplementation on performance in professional young soccer players during a competitive season. J Int Soc Sports Nutr. PMID 34663363. Full-season RCT.
del Favero S, et al. (2012). Creatine but not betaine supplementation increases muscle phosphorylcreatine content and strength performance. Amino Acids. PMID 21744011. Head-to-head MRS-PCr trial. DEBUNKS creatine-mimetic claim.
Aziz M, et al. (2023). Betaine supplementation improves CrossFit performance and increases testosterone levels, but has no influence on Wingate power: randomized controlled trial. PMID 37409757. Single unreplicated testosterone finding.
Branch JD, et al. (2020). Betaine Supplementation Does Not Improve Muscle Hypertrophy or Strength Following 6 Weeks of Cross-Fit Training. PMID 32516959. NULL primary.
Apicella JM, et al. (2013). Betaine supplementation enhances anabolic endocrine and Akt signaling in response to acute bouts of exercise. Eur J Appl Physiol. PMID 22976217. Biomarker RCT.
Cholewa JM, et al. (2014). Effects of betaine on body composition, performance, and homocysteine thiolactone. J Int Soc Sports Nutr. PMC3844502 [cite-unverified]. Single positive body-composition RCT.
Craig SA. (2004). Betaine in human nutrition. Am J Clin Nutr [cite-unverified]. Landmark narrative review.